Jim Simons Compass Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 222,600 shares of CMPX stock, worth $307,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares

222,600

Previous 140,600 58.32%

Holding current value

$307,188

Previous $140,000 192.14%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.8 - $1.88 $65,600 - $154,160	82,000 Added 58.32%	222,600 $409,000
Q2 2024 Aug 09, 2024	BUY	$1.0 - $1.85 $70,200 - $129,870	70,200 Added 99.72%	140,600 $140,000
Q1 2024 May 13, 2024	SELL	$1.2 - $2.29 $127,678 - $243,653	-106,399 Reduced 60.18%	70,400 $139,000
Q4 2023 Feb 13, 2024	BUY	$1.4 - $1.98 $209,998 - $296,998	149,999 Added 559.7%	176,799 $276,000
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $50,116 - $87,100	26,800 New	26,800 $53,000
Q1 2023 May 12, 2023	BUY	$3.14 - $5.48 $1,256 - $2,192	400 Added 0.77%	52,300 $171,000
Q4 2022 Feb 13, 2023	SELL	$2.55 - $5.41 $31,403 - $66,624	-12,315 Reduced 19.18%	51,900 $261,000
Q3 2022 Nov 14, 2022	SELL	$1.9 - $3.37 $3,705 - $6,571	-1,950 Reduced 2.95%	64,215 $146,000
Q2 2022 Aug 12, 2022	BUY	$1.43 - $3.1 $75,596 - $163,881	52,865 Added 397.48%	66,165 $175,000
Q1 2022 May 13, 2022	BUY	$1.25 - $3.5 $16,625 - $46,550	13,300 New	13,300 $18,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

91.9M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $140M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account